Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

Standard Dose
EQ 200MG BASE/5ML;EQ 600MG BASE/5ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL is listed in Drugs@FDA under application 062759 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL Form and strength GRANULE;ORAL - EQ 200MG BASE/5ML;EQ 600MG BASE/5ML Sponsor BARR Submission history Latest submission status date: 2015-12-16 00:00:00.

Structured Monograph

Clinical summary

Approval overview ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL is listed in Drugs@FDA under application 062759 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL Form and strength GRANULE;ORAL - EQ 200MG BASE/5ML;EQ 600MG BASE/5ML Sponsor BARR Submission history Latest submission status date: 2015-12-16 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL (ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL) | Drug Monograph | MedicHelpline